HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD.

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

002693

CNE100001K63

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 24/06/2024 am IST			5-day change	1st Jan Change
4.28 ^CNY	-5.93%		-6.55%	-43.01%

22/05	Workshop of Shuangcheng Pharma's Unit Passes Regulatory Inspection; Shares Up 3%	MT
07/05	Shuangcheng Pharma Gets FDA Nod to Market Acromegaly Drug in US	MT

Hainan Shuangcheng Pharmaceuticals Co., Ltd. Approves Election of Shang Xiaogang as Independent Directors

January 18, 2020 at 01:02 am IST

Hainan Shuangcheng Pharmaceuticals Co., Ltd. approved election of Shang Xiaogang as independent directors in the Extraordinary General Meeting of 2020 on 16 January 2020.

Latest news about Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Workshop of Shuangcheng Pharma's Unit Passes Regulatory Inspection; Shares Up 3%	22/05	MT
Shuangcheng Pharma Gets FDA Nod to Market Acromegaly Drug in US	07/05	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
Hainan Shuangcheng Pharma's Unit Gets Green Light to Market Pregabalin Capsules	18/03	MT
Shuangcheng Pharmaceutical Gets Nod to Market Anticoagulant in Saudi Arabia	15/03	MT
Shuangcheng Pharma Unit Passes US FDA On-Site Inspection	26/01	MT
Shuangcheng Pharma Shuangcheng Pharmaceutical Secures Pakistan Approval for Hepatitis, Tumor Drug	04/01	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Shuangcheng Pharma Flags 20 Million Yuan of Unrecovered Financial Products	05/23/05	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
Shuangcheng Pharma Receives Nod to Produce Aseptic Products in Saudi Arabia	28/23/28	MT
Shuangcheng Pharmaceutical Gets Drug Production License	12/23/12	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Shuangcheng Pharma Applies to Have Stomach Drug Added to China’s Drug Procurement Scheme	30/23/30	MT
Hainan Shuangcheng Pharmaceutical Finalizes Transfer of Drug Rights	12/23/12	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Announces Board Appointments	11/23/11	CI
Hainan Shuangcheng Pharmaceuticals Sells Injection Product Rights for 32 Million Yuan	05/23/05	MT
Shuangcheng Pharmaceuticals Europe S.r.l announced that it has received €0.05 million in funding from Hainan Shuangcheng Pharmaceuticals Co., Ltd.	08/22/08	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Hainan Shuangcheng Subsidiary Agrees to Paclitaxel Production	26/22/26	MT
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	12/22/12	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/22/29	CI
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	29/22/29	CI

Chart Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Duration

Period

Chart Hainan Shuangcheng Pharmaceuticals Co., Ltd.

More charts

Hainan Shuangcheng Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the production, sale, research and development of chemically synthesized peptide drugs. The Company's main products include Jitai (thymalfasin for injection), for the treatment of various types of liver diseases, cancers, geriatric deseases and infectious diseases; thymopentin for infection; somatostatin, for the treatment of severe acute esophageal variceal bleeding and severe acute stomach or for the adjuvant therapy of duodenal ulcer bleeding and diabetic ketoacidosis, as well as other drugs. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD.	-43.01%	250M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.41%	43.29B
OTSUKA HOLDINGS CO., LTD.	+27.64%	22.38B
SANDOZ GROUP AG	+19.96%	15.51B
CIPLA LIMITED	+18.83%	14.52B
ZYDUS LIFESCIENCES LIMITED	+54.68%	12.93B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.39%	6.56B
ASPEN PHARMACARE HOLDINGS LIMITED	+17.73%	5.87B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals